Lung Adenocarcinoma with EGFR Exon 20 H773_V774delinsLM Mutation
Sensitive to Furmonertinib: A Case Report.
10.3779/j.issn.1009-3419.2025.102.19
- Author:
Rongzhen LI
1
;
Yan XU
1
;
Xiaoxing GAO
1
;
Minjiang CHEN
1
;
Wei ZHONG
1
;
Mengzhao WANG
1
Author Information
1. Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
- Publication Type:English Abstract
- Keywords:
EGFR mutations;
Furmonertinib;
Lung neoplasms;
Rare mutations
- MeSH:
Humans;
Adenocarcinoma/genetics*;
Adenocarcinoma of Lung;
ErbB Receptors/genetics*;
Exons/genetics*;
Lung Neoplasms/enzymology*;
Mutation;
Protein Kinase Inhibitors/therapeutic use*
- From:
Chinese Journal of Lung Cancer
2025;28(6):477-481
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor (EGFR) exon 20 mutations represent a rare subset of genetic alterations in non-small cell lung cancer (NSCLC). Among them, the complex mutation H773_V774delinsLM is exceedingly uncommon, accounting for only 0.2%-1% of all EGFR mutations. It is currently believed that rare EGFR mutations are generally resistant to the first- and second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Although the third-generation EGFR-TKIs have shown some efficacy in certain rare mutations, clinical evidence regarding their use in NSCLC patients with the H773_V774delinsLM mutation remains sparse, and their efficacy and safety are yet to be clarified. Here, we present the first documented case of a patient with EGFR H773_V774delinsLM-mutant lung adenocarcinoma who experienced remarkable tumor regression following treatment with furmonertinib. This case highlights the potential utility of furmonertinib in treating patients with this rare EGFR mutation and may provide valuable insight into emerging treatment strategies for similarly affected patients.
.
